BRAF V600E Mutations In Papillary Thyroid Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01417442|
Recruitment Status : Unknown
Verified August 2011 by Bezmialem Vakif University.
Recruitment status was: Recruiting
First Posted : August 16, 2011
Last Update Posted : August 16, 2011
|Condition or disease||Intervention/treatment||Phase|
|Papillary Thyroid Carcinoma||Genetic: BRAF V600E POSITIVITY||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma|
|Study Start Date :||July 2011|
|Estimated Primary Completion Date :||July 2012|
|Estimated Study Completion Date :||July 2012|
Experimental: BRAF V600E POSITIVITY
This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor.
Genetic: BRAF V600E POSITIVITY
BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
- BRAF V600E MUTATION [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01417442
|Yeliz Emine Ersoy||Recruiting|
|Istanbul, Turkey, 34308|
|Contact: Yeliz E Ersoy, DR +905326102713 email@example.com|
|Principal Investigator: Yeliz E Ersoy, M.D.|